基于生理药代动力学模型预测地司美拉酮(MT-7117)的潜在药物相互作用
本研究利用生理药代动力学(PBPK)模型预测地司美拉酮与转运体底物药物(如阿托伐他汀、瑞舒伐他汀)的相互作用。模拟显示地司美拉酮100mg和200mg可使阿托伐他汀和瑞舒伐他汀的系统暴露量增加,但预测变化无临床显著性,建议谨慎并适当临床监测。
要点
- 地司美拉酮100mg使阿托伐他汀AUC增1.25倍,200mg增1.45倍
- 地司美拉酮100mg使瑞舒伐他汀AUC增1.34倍,200mg增1.69倍
- 预测暴露变化无临床显著性,但联用仍需谨慎监测
核心结论
- PBPK模型预测地司美拉酮100或200mg与阿托伐他汀或瑞舒伐他汀联用时,血浆暴露量变化无临床显著性,但建议谨慎并适当临床监测。
研究设计与样本
- 基于计算机模拟、体外和体内数据构建地司美拉酮的PBPK模型,评估其与CYP3A、P-gp、OATP1B1/1B3、OAT3和BCRP底物药物的DDI潜力。
主要发现
- 与地司美拉酮100mg联用时,阿托伐他汀Cmax和AUC分别增加1.21倍和1.25倍;与200mg联用时分别增加1.42倍和1.45倍。
- 与地司美拉酮100mg联用时,瑞舒伐他汀Cmax和AUC分别增加1.67倍和1.34倍;与200mg联用时分别增加2.40倍和1.69倍。
临床怎么用
- 临床联用地司美拉酮与阿托伐他汀或瑞舒伐他汀时,无需常规调整剂量,但应谨慎并适当监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Dersimelagon is a novel, investigational, orally administered, selective agonist of the melanocortin-1 receptor that has demonstrated efficacy at increasing symptom-free light exposure and an acceptable safety profile in patients with protoporphyria. A phase 1 drug-drug interaction (DDI) study demonstrated that dersimelagon 300 mg has the potential for clinically relevant DDIs with drugs that are substrates for breast cancer resistance protein, such as atorvastatin and rosuvastatin. This study uses physiologically based pharmacokinetic (PBPK) modelling to further investigate the DDI effects at lower doses of dersimelagon with substrate drugs. METHODS: The data from in silico, in vitro and in vivo studies were used to construct a PBPK model for dersimelagon to assess the DDI potential between dersimelagon and substrate drugs for cytochrome P450 3A, P-glycoprotein, organic anion transporting polypeptide 1B1/1B3, organic anion transporter 3 and breast cancer resistance protein, including atorvastatin and rosuvastatin. RESULTS: The systemic exposure of atorvastatin based on the maximum plasma concentration and area under the plasma concentration-time curve was predicted to increase 1.21-fold and 1.25-fold, respectively, if coadministered with dersimelagon 100 mg, and 1.42-fold and 1.45-fold with dersimelagon 200 mg. The systemic exposure of rosuvastatin followed trends similar to atorvastatin (1.67-fold and 1.34-fold increase in maximum plasma concentration and area under the plasma concentration-time curve, respectively, with dersimelagon 100 mg, and 2.40-fold and 1.69-fold with dersimelagon 200 mg). CONCLUSION: Overall, PBPK modelling results indicate that the simulated changes in plasma exposure of atorvastatin and rosuvastatin following coadministration with dersimelagon 100 or 200 mg are not clinically significant, but caution and appropriate clinical monitoring should be recommended.
引用
- Ogasawara A, Kojima K, Murata Y, et al. Physiologically based pharmacokinetic modelling to predict potential drug-drug interactions of dersimelagon (MT-7117). Br J Clin Pharmacol. 2024. PMID: 39367654. doi:10.1111/bcp.16271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。